boston.com Your Life your connection to The Boston Globe
White Coat Notes: News from the Boston-area medical community
Comments
Send your comments and tips to whitecoat@globe.com
Categories


Blogger
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Contributors
Boston Globe Health and Science staff:
Scott Allen
Alice Dembner
Carey Goldberg
Liz Kowalczyk
Stephen Smith
Colin Nickerson
Beth Daley
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
 Short White Coat blogger Ishani Ganguli
 Short White Coat blogger Jennifer Srygley
Week of: November 11
Week of: November 4
Week of: October 28
Week of: October 21
Week of: October 14
Week of: October 7

« On the blogs: Swiss healthcare parallels, latest hospital infection rates | Main | Children's hires Jamaica Plain health center head »

Tuesday, May 22, 2007

Today's Globe: diabetes drug and heart risks, pitching health insurance, stent rivals

avandia.jpgAvandia, the world's top-selling oral diabetes drug, significantly increases the risk of heart attacks, a prominent cardiologist said in an article that the New England Journal of Medicine deemed important enough to post on its website yesterday, weeks before the scheduled print publication date. Patients taking Avandia should not abruptly stop the drug, the FDA said. Instead, they should meet with their doctors to discuss their risk of a heart attack and how well their diabetes is controlled, according to Dr. Larry C. Deeb, president of medicine and science for the American Diabetes Association.

hc ad150.bmpJon Kingsdale, executive director of the Commonwealth Health Insurance Connector Authority, which is overseeing implementation of the state's healthcare revamp, will gather with state political leaders and Red Sox executives today at Fenway Park to unveil a $3 million advertising campaign (above) that is heavily tied to the Red Sox and will be featured on the team's cable television outlet, New England Sports Network.

Medtronic Inc. will report today that its stent for preventing heart attacks didn't cause blood clots in tests, increasing the company's chances of expanding its share of the $5.4 billion-a-year worldwide market. The results, to be presented at a scientific meeting in Barcelona, suggest that experimental devices may be safer than those sold by Johnson & Johnson and Boston Scientific Corp.

Posted by Elizabeth Cooney at 06:28 AM
Sponsored Links